Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy.

McHugh, Lynsey A; Kriajevska, Marina; Mellon, John K; Griffiths, Thomas R

McHugh, Lynsey A; Kriajevska, Marina; Mellon, John K; Griffiths, Thomas R.

Affiliation

McHugh LA; Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, United Kingdom. lamchugh@doctors.org.uk

Urology ; 69(2): 390-4, 2007 Feb.

Article in En | MEDLINE | ID: mdl-17320695

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/pharmacology; Cell Proliferation/drug effects; Quinazolines/pharmacology; Analysis of Variance; Cell Line, Tumor/drug effects; Cell Survival/drug effects; Cisplatin/pharmacology; Deoxycytidine/analogs & derivatives; Deoxycytidine/pharmacology; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Humans; Lapatinib; Receptor, ErbB-2/drug effects; Receptor, ErbB-2/metabolism; Sensitivity and Specificity; Urinary Bladder Neoplasms/drug therapy; Urinary Bladder Neoplasms/pathology; Gemcitabine

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Antineoplastic Combined Chemotherapy Protocols / Cell Proliferation Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Urology Year: 2007 Document type: Article Affiliation country: United kingdom Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links